Bevacizumab and ovarian cancer.
| Autor: | Lai GG; Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA., Penson RT |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2011 Sep; Vol. 47 (9), pp. 669-81. |
| DOI: | 10.1358/dot.2011.47.9.1673557 |
| Abstrakt: | Epithelial ovarian cancer is the most lethal of gynecologic malignancies in the United States, with a significant proportion of patients with advanced disease achieving clinical remission with conventional treatment approaches, but dying of recurrence. Bevacizumab is a first-in-class antiangiogenic. This recombinant humanized monoclonal antibody neutralizes vascular endothelial growth factor (VEGF) and inhibits endothelial and tumor cell activation and proliferation. It has a low clearance and long elimination half-life, supporting a convenient 2- or 3-weekly dosing schedule. It is generally well tolerated, although trials have highlighted some toxicity-related concerns, notably gastrointestinal perforation. Phase III trials that evaluate overall survival are not yet mature, and cost-effectiveness of bevacizumab is hotly debated. As more evidence for the role of anti-VEGF agents in augmenting therapy and inducing durable tumor dormancy continues to emerge, it is anticipated that antiangiogenic therapy will play an important role in the management ovarian malignancy. (Copyright 2011 Prous Science, S.A.U. or its licensors. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|